TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy
Brief Summary: This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.


Options:
A: Arm Label: ABT-199 after ibrutinib therapy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after idelalisib therapy; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after ibrutinib therapy: Expansion Cohort; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Arm Label: ABT-199 after idelalisib therapy: Expansion Cohort; Type: EXPERIMENTAL; Interventions: Drug: Venetoclax | Intervention Type: DRUG; Name: Venetoclax; Assigned to Arm(s): ABT-199 after ibrutinib therapy, ABT-199 after ibrutinib therapy: Expansion Cohort, ABT-199 after idelalisib therapy, ABT-199 after idelalisib therapy: Expansion Cohort
B: Arm Label: Arm A (PCO, closed to accrual as of 8/23/2011); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Arm Label: Arm B (PCO with ofatumumab consolidation); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: BIOLOGICAL; Name: Ofatumumab; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation)
C: Arm Label: Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab | Arm Label: Physicians' Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Physicians' Choice | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Ofatumumab | Intervention Type: DRUG; Name: Physicians' Choice; Assigned to Arm(s): Physicians' Choice
D: Arm Label: Lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide | Intervention Type: DRUG; Name: Lenalidomide; Assigned to Arm(s): Lenalidomide

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Plasticity-based, Adaptive, Computerized Cognitive Remediation Treatment (PACR) for Adults With Multiple Sclerosis (MS)
Brief Summary: Cognitive impairment remains a major disability for individuals with multiple sclerosis (MS). The primary objective of this study is to evaluate the efficacy for treating MS-associated cognitive deficits using a unique computer-based plasticity-based and adaptive cognitive remediation treatment (PACR) compared to a computer-based control. This novel cognitive remediation approach has led to striking improvements in cognitive functioning in other disorders (schizophrenia, traumatic brain injury, aging, and dementia) but has never been applied to individuals with MS. The investigators will enroll 136 MS participants who will be randomized in a 2:1 pattern to complete either the treatment or control condition for 60 hours across a 12-week treatment period. Both the treatment and control conditions will be accessed remotely by the subjects from a study-provided laptop computer. Study outcomes will include program compliance, performance on study tasks and neuropsychological measures, quality of life and functional status. Given the success of this program with other disorders and strong preliminary data from our feasibility study, the investigators believe PACR is an exciting untapped opportunity to improve cognition in individuals with MS.


Options:
A: Arm Label: Intensive Training; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Training | Arm Label: Normal Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Normal Training | Intervention Type: BEHAVIORAL; Name: Intensive Training; Assigned to Arm(s): Intensive Training | Intervention Type: BEHAVIORAL; Name: Normal Training; Assigned to Arm(s): Normal Training
B: Arm Label: Experimental Group; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive rehabilitation | Arm Label: Standard Psychological care; Type: SHAM_COMPARATOR; Interventions: Behavioral: Standard Psychological care | Intervention Type: BEHAVIORAL; Name: Cognitive rehabilitation; Assigned to Arm(s): Experimental Group | Intervention Type: BEHAVIORAL; Name: Standard Psychological care; Assigned to Arm(s): Standard Psychological care
C: Arm Label: Self-generation treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Self-generation treatment | Arm Label: memory training; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-generation treatment; Assigned to Arm(s): Self-generation treatment
D: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Other: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation) | Arm Label: Treatment B; Type: ACTIVE_COMPARATOR; Interventions: Other: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation) | Intervention Type: OTHER; Name: PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation); Assigned to Arm(s): Treatment A, Treatment B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy
Brief Summary: The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.


Options:
A: Intervention Type: DRUG; Name: beclomethasone dipropionate plus formoterol fumarate combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate plus salmeterol xinafoate combination; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide and placebo | Intervention Type: DRUG; Name: budesonide/formoterol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide and placebo; Assigned to Arm(s): 2
D: Arm Label: FS MDPI 200 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: FS MDPI 100 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI, Drug: Albuterol/salmeterol HFA MDI | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI | Intervention Type: DRUG; Name: Albuterol/salmeterol HFA MDI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg, Placebo MDPI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy
Brief Summary: The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.


Options:
A: Intervention Type: DRUG; Name: fluticasone propionate/salmeterol powder; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: fluticasone propionate powder; Assigned to Arm(s): N/A
B: Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI | Arm Label: Fp MDPI 25 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: Fp MDPI 50 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate | Arm Label: FS MDPI 50/12.5 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Propionate/Salmeterol | Intervention Type: DRUG; Name: Fluticasone Propionate; Assigned to Arm(s): Fp MDPI 25 mcg BID, Fp MDPI 50 mcg BID | Intervention Type: DRUG; Name: Fluticasone Propionate/Salmeterol; Assigned to Arm(s): FS MDPI 50/12.5 mcg BID | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Symbicort pMDI | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: budesonide pMDI | Intervention Type: DRUG; Name: Symbicort pMDI; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: budesonide pMDI; Assigned to Arm(s): 2
D: Arm Label: FS MDPI 200 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: FS MDPI 100 / 12.5 mcg; Type: EXPERIMENTAL; Interventions: Drug: FS MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 200 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Fp MDPI 100 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fp MDPI, Drug: Albuterol/salmeterol HFA MDI | Arm Label: Placebo MDPI; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo MDPI, Drug: Albuterol/salmeterol HFA MDI | Intervention Type: DRUG; Name: FS MDPI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg | Intervention Type: DRUG; Name: Fp MDPI; Assigned to Arm(s): Fp MDPI 100 mcg, Fp MDPI 200 mcg | Intervention Type: DRUG; Name: Placebo MDPI; Assigned to Arm(s): Placebo MDPI | Intervention Type: DRUG; Name: Albuterol/salmeterol HFA MDI; Assigned to Arm(s): FS MDPI 100 / 12.5 mcg, FS MDPI 200 / 12.5 mcg, Fp MDPI 100 mcg, Fp MDPI 200 mcg, Placebo MDPI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial
Brief Summary: The aim of this group-randomized trial was to test the effectiveness of a new comprehensive program, which the investigators called CALMA -plus, in increasing controller medication use and reducing asthma symptoms. CALMA-plus involved the CALMA home-based family intervention, plus educational training of physicians and nurses, as well as screening for asthma in clinics serving Medicaid island Puerto Rican children with asthma. Because the provider training was expected to have an impact on the entire clinical setting where trained providers work, as well as the patients using that setting, the investigators randomized clinic groups rather than individual patients. The investigators compared the CALMA-Plus intervention to a CALMA-only group, which the investigators expected to obtain the same benefits as the investigators have previously documented.


Options:
A: Arm Label: DAS181 Dry Powder 10 mg qd x 3 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: DAS181 dry powder, formulation F02 | Arm Label: Lactose Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Respitose ML006 (DMV-Fonterra) | Intervention Type: DRUG; Name: DAS181 dry powder, formulation F02; Assigned to Arm(s): DAS181 Dry Powder 10 mg qd x 3 days | Intervention Type: DRUG; Name: Respitose ML006 (DMV-Fonterra); Assigned to Arm(s): Lactose Placebo
B: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose
D: Arm Label: Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial
Brief Summary: The aim of this group-randomized trial was to test the effectiveness of a new comprehensive program, which the investigators called CALMA -plus, in increasing controller medication use and reducing asthma symptoms. CALMA-plus involved the CALMA home-based family intervention, plus educational training of physicians and nurses, as well as screening for asthma in clinics serving Medicaid island Puerto Rican children with asthma. Because the provider training was expected to have an impact on the entire clinical setting where trained providers work, as well as the patients using that setting, the investigators randomized clinic groups rather than individual patients. The investigators compared the CALMA-Plus intervention to a CALMA-only group, which the investigators expected to obtain the same benefits as the investigators have previously documented.


Options:
A: Arm Label: family diabetes management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: family diabetes management intervention | Intervention Type: BEHAVIORAL; Name: family diabetes management intervention; Assigned to Arm(s): family diabetes management intervention
B: Arm Label: CAPS; Type: EXPERIMENTAL; Interventions: Behavioral: Counselor-assisted problem solving (CAPS) | Arm Label: IRC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-resource comparison (IRC) | Intervention Type: BEHAVIORAL; Name: Counselor-assisted problem solving (CAPS); Assigned to Arm(s): CAPS | Intervention Type: BEHAVIORAL; Name: Internet-resource comparison (IRC); Assigned to Arm(s): IRC
C: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
D: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial
Brief Summary: The aim of this group-randomized trial was to test the effectiveness of a new comprehensive program, which the investigators called CALMA -plus, in increasing controller medication use and reducing asthma symptoms. CALMA-plus involved the CALMA home-based family intervention, plus educational training of physicians and nurses, as well as screening for asthma in clinics serving Medicaid island Puerto Rican children with asthma. Because the provider training was expected to have an impact on the entire clinical setting where trained providers work, as well as the patients using that setting, the investigators randomized clinic groups rather than individual patients. The investigators compared the CALMA-Plus intervention to a CALMA-only group, which the investigators expected to obtain the same benefits as the investigators have previously documented.


Options:
A: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback of patient adherence information | Arm Label: II; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active control group | Intervention Type: BEHAVIORAL; Name: Feedback of patient adherence information; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Active control group; Assigned to Arm(s): II
C: Arm Label: Interactive SMS; Type: EXPERIMENTAL; Interventions: Other: Interactive SMS | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Interactive SMS; Assigned to Arm(s): Interactive SMS | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
B: Arm Label: bilateral limb ischemic preconditioning (BLIPC); Type: EXPERIMENTAL; Interventions: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: bilateral limb ischemic preconditioning (Doctormate, IPC-906X); Assigned to Arm(s): bilateral limb ischemic preconditioning (BLIPC)
C: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Procedure: remote ischemic preconditioning | Arm Label: placebo remote ischemic preconditioning; Type: SHAM_COMPARATOR; Interventions: Procedure: sham remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: PROCEDURE; Name: sham remote ischemic preconditioning; Assigned to Arm(s): placebo remote ischemic preconditioning
D: Arm Label: Thrombolysis + Remote perconditioning; Type: EXPERIMENTAL; Interventions: Procedure: Thrombolysis + remote perconditioning | Arm Label: Thrombolysis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Actilyse | Intervention Type: DRUG; Name: Actilyse; Assigned to Arm(s): Thrombolysis | Intervention Type: PROCEDURE; Name: Thrombolysis + remote perconditioning; Assigned to Arm(s): Thrombolysis + Remote perconditioning

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)
Brief Summary: The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
B: Arm Label: thrombectomy; Type: EXPERIMENTAL; Interventions: Procedure: Thrombectomy, Device: Stentriever Solitaire FR® or Penumbra System® | Arm Label: best medical treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Thrombectomy; Assigned to Arm(s): thrombectomy | Intervention Type: DEVICE; Name: Stentriever Solitaire FR® or Penumbra System®; Assigned to Arm(s): thrombectomy
C: Arm Label: Trevo Thrombectomy Procedure; Type: EXPERIMENTAL; Interventions: Device: Trevo Thrombectomy Procedure, Other: Medical Management | Arm Label: Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical Management | Intervention Type: DEVICE; Name: Trevo Thrombectomy Procedure; Assigned to Arm(s): Trevo Thrombectomy Procedure | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Medical Management, Trevo Thrombectomy Procedure
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2

Answer: C